CTAB.F Stock Overview
A phytopharmaceutical company, engages in the research and development of advanced pharmaceutical grade formulations of cannabinoids in Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Canntab Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.0091 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 11 Month Change | -99.00% |
| 3 Month Change | n/a |
| 1 Year Change | -99.95% |
| 33 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| CTAB.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 3.4% | 1.6% |
| 1Y | -100.0% | 14.2% | 32.3% |
Return vs Industry: CTAB.F underperformed the US Pharmaceuticals industry which returned 14.2% over the past year.
Return vs Market: CTAB.F underperformed the US Market which returned 32.3% over the past year.
Price Volatility
| CTAB.F volatility | |
|---|---|
| CTAB.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CTAB.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine CTAB.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Richard Goldstein | canntab.ca |
Canntab Therapeutics Limited, a phytopharmaceutical company, engages in the research and development of advanced pharmaceutical grade formulations of cannabinoids in Canada. It offers oral dosage formulations of pharmaceutical cannabis, including sustained release cannabinoid formulations and pellets, immediate release cannabidiol formulations, modified-release multi-layer cannabinoid formulations, flash-melt cannabinoid formulations, and bi-layer cannabinoid tablets for treating sleep disorders, post-traumatic stress disorder, social anxiety, addiction, arthritis, general pain, pain management and appetite loss associated with cancer treatments, and addiction treatment therapy of opioids and other painkillers. Canntab Therapeutics Limited is headquartered in Markham, Canada.
Canntab Therapeutics Limited Fundamentals Summary
| CTAB.F fundamental statistics | |
|---|---|
| Market cap | US$38.00 |
| Earnings (TTM) | -US$2.39m |
| Revenue (TTM) | US$52.40k |
0.0x
P/S Ratio0.0x
P/E RatioIs CTAB.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CTAB.F income statement (TTM) | |
|---|---|
| Revenue | CA$73.48k |
| Cost of Revenue | CA$1.40m |
| Gross Profit | -CA$1.33m |
| Other Expenses | CA$2.03m |
| Earnings | -CA$3.36m |
Last Reported Earnings
Feb 28, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did CTAB.F perform over the long term?
See historical performance and comparison